Journal Title
Title of Journal: Curr Colorectal Cancer Rep
|
Abbravation: Current Colorectal Cancer Reports
|
|
|
|
|
|
|
|
Authors: Elisa Fontana Krisztian Homicsko Katherine Eason Anguraj Sadanandam
Publish Date: 2016/10/17
Volume: 12, Issue: 6, Pages: 296-302
Abstract
Although surgery for earlystage colorectal cancer CRC is often curative many patients require adjuvant chemotherapy to treat micrometastatic disease and to reduce the risk of recurrence Targeted therapies have improved outcomes for patients with metastatic disease but in the adjuvant setting options are limited to a fluoropyrimidine alone or in combination with oxaliplatin There is an unmet need for new predictive biomarkers to personalise treatment in the adjuvant setting With goals to address this gap and to better characterise disease heterogeneity several groups including our own have identified three to six gene expression subtypes that were later consolidated into consensus molecular subtypes as part of the Colorectal Cancer Subtyping Consortium CRCSC effort In this review we discuss the differences and similarities between these subtypes and their potential prognostic and predictive values We question whether a personalised treatment approach based on CRC subtypes might be beneficial in the adjuvant setting to improve treatment options and ultimately patient outcomesAnguraj Sadanandam has received financial support through a grant from BristolMyers Squibb via the International ImmunoOncology Network and holds a patent on colorectal cancer classification with different prognosis and personalized therapeutic responses application number PCT/IB2013/060416 with royalties paid
Keywords:
.
|
Other Papers In This Journal:
|